<DOC>
	<DOCNO>NCT00346814</DOCNO>
	<brief_summary>Purpose : Retinopathy prematurity ( ROP ) continue tobe major cause blindness child . Although ablation retina laser cryotherapy reduces incidence blindness suppress neovascular phase ROP visual outcomes treatment often poor . Vascular endothelial growth factor ( VEGF ) important role pathogenesis ROP inhibition VEGF expression neovascular phase might prevent destructive neovascularization ROP . The aim study determine safety efficacy intravitreal bevacizumab treatment retinopathy prematurity</brief_summary>
	<brief_title>Antiangiogenic Therapy With Bevacizumab Retinopathy Prematurity . Structural Outcome</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Retinopathy prematurity stage III , IV V treat laser cryotherAPY PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Retinopathy prematurity</keyword>
	<keyword>antiangiogenic therapy</keyword>
</DOC>